SBIR/STTR Research Award

Cytoprotective Effects of UPR Modulators in ER Stress-Challenged beta-Cells

Award identifier ea2be097cf8eaeb1c8750636651c65350b3bef1cf328058749c31b803ef6ec15Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$152,520

Program and phase

STTR · Phase I

Award year

2009

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
METAFOLD THERAPEUTICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2009-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Type 2 diabetes mellitus (T2D) affects 18 million Americans, with national healthcare and lost productivity costs exceeding 100 billion per year. T2D begins as a state of compensated insulin resistance; frank disease develops when approximately 50% of insulin-producing pancreatic islet -cells of affected individuals undergo cell death. Numerous recent studies link T2D to endoplasmic reticulum (ER) stress, a condition that occurs whenever protein folding requirements overwhelm protein-folding capacity in the secretory pathway. Notably, there is mounting evidence that ER stress contributes to diminished glucose-responsive insulin secretion in -cells, to -cell apoptosis, and to general peripheral insulin resistance, all hallmarks of T2D. ER stress triggers the unfolded protein response (UPR) pathway, which slows translation and transcriptionally upregulates genes that enhance ER protein-folding capabilities. If homeostasis is not restored through these outputs, the UPR triggers apoptosis instead. We hypothesize that a key component of the UPR, Ire1a, acts as a toggling switch between homeostatic and apoptotic outputs, ultimately controlling -cell fate. The project goal of this STTR is to identify a small molecule that biases Ire1a.s outputs towards homeostasis and evaluate its therapeutic potential by demonstrating cytoprotective effects in -cell-derived cell lines. We have developed a novel biochemical assay to detect such compounds, with hits already identified. Structure-based design will guide our medicinal chemistry to provide increasingly potent cytoprotective agents. Results from the proposed studies will guide our selection of lead compounds to validate this approach in disease-relevant animal models of -cell function and capacity. Ultimately, these studies represent significant early steps to develop a novel, oral treatment for the improvement of glycemic control in type 2 diabetics with the unique potential to modify disease progression.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.